Checkpoint Therapeutics Announces Positive Interim Results from Registration-Enabling Trial of Cosibelimab in Metastatic Cutaneous Squamous Cell Carcinoma
September 17, 2020 06:30 ET
|
Checkpoint Therapeutics, Inc
51.4% objective response rate and 13.5% complete response rate in half the planned pivotal cohortInterim results presented at ESMO Virtual Congress 2020On track to report full top-line results in...
Checkpoint Therapeutics to Participate in Three September 2020 Virtual Investor Conferences
September 10, 2020 08:00 ET
|
Checkpoint Therapeutics, Inc
NEW YORK, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James F....
Checkpoint Therapeutics to Present at Virtual Corporate Access Summit Hosted by B. Riley FBR on Wednesday, August 19, 2020
August 17, 2020 08:00 ET
|
Checkpoint Therapeutics, Inc
NEW YORK, Aug. 17, 2020 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James F....
Checkpoint Therapeutics Reports Second Quarter 2020 Financial Results and Recent Corporate Highlights
August 05, 2020 16:30 ET
|
Checkpoint Therapeutics, Inc
NEW YORK, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company focused on the acquisition,...
Checkpoint Therapeutics to Present Cosibelimab Interim Results from Registration-Enabling Trial at ESMO Virtual Congress 2020
July 27, 2020 07:30 ET
|
Checkpoint Therapeutics, Inc
Presentation to highlight updated interim data from global trial in patients with metastatic cutaneous squamous cell carcinomaOver 50% of enrollment target achieved; full enrollment expected around...
Checkpoint Therapeutics to Host Virtual Annual Meeting of Stockholders
May 22, 2020 08:30 ET
|
Checkpoint Therapeutics, Inc
NEW YORK, May 22, 2020 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it will...
Checkpoint Therapeutics Reports First Quarter 2020 Financial Results and Recent Corporate Highlights
May 06, 2020 16:30 ET
|
Checkpoint Therapeutics, Inc
NEW YORK, May 06, 2020 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company focused on the acquisition,...
Checkpoint Therapeutics Announces Issuance of U.S. Composition of Matter Patent for Anti-PD-L1 Antibody Cosibelimab
April 21, 2020 08:00 ET
|
Checkpoint Therapeutics, Inc
- U.S. patent protection through at least May 2038- Registration-enabling study of cosibelimab in cutaneous squamous cell carcinoma over one-third enrolled NEW YORK, April 21, 2020 (GLOBE NEWSWIRE)...
Checkpoint Therapeutics Reports Full-Year 2019 Financial Results and Recent Corporate Highlights
March 11, 2020 16:15 ET
|
Checkpoint Therapeutics, Inc
NEW YORK, March 11, 2020 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage, immuno-oncology biopharmaceutical company focused on the acquisition,...
Checkpoint Therapeutics Announces Confirmation of Registration Path for Cosibelimab in Metastatic Cutaneous Squamous Cell Carcinoma
January 13, 2020 08:15 ET
|
Checkpoint Therapeutics, Inc
FDA feedback supports plan to submit Biologics License Application (BLA) based on data from ongoing Phase 1 trialOne-third enrollment complete in cohort of patients with metastatic cutaneous squamous...